ID   M3K1_HUMAN              Reviewed;        1512 AA.
AC   Q13233;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 4.
DT   15-MAR-2017, entry version 174.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 1;
DE            EC=2.7.11.25;
DE   AltName: Full=MAPK/ERK kinase kinase 1;
DE            Short=MEK kinase 1;
DE            Short=MEKK 1;
GN   Name=MAP3K1; Synonyms=MAPKKK1, MEKK, MEKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-1512, FUNCTION, AND INTERACTION WITH
RP   MAP2K4.
RX   PubMed=9808624; DOI=10.1101/gad.12.21.3369;
RA   Xia Y., Wu Z., Su B., Murray B., Karin M.;
RT   "JNKK1 organizes a MAP kinase module through specific and sequential
RT   interactions with upstream and downstream components mediated by its
RT   amino-terminal extension.";
RL   Genes Dev. 12:3369-3381(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1238-1274.
RC   TISSUE=Leukocyte;
RX   PubMed=8597633; DOI=10.1007/BF00539003;
RA   Vinik B.S., Kay E.S., Fiedorek F.T. Jr.;
RT   "Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and
RT   human chromosome 5.";
RL   Mamm. Genome 6:782-783(1995).
RN   [4]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.M208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for
RT   JNK activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [5]
RP   INTERACTION WITH AXIN1.
RX   PubMed=15262978; DOI=10.1074/jbc.M404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal
RT   kinase activation by Axin and dishevelled through distinct
RT   mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154 AND SER-1043, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [8]
RP   INTERACTION WITH STK38.
RX   PubMed=17906693; DOI=10.1038/sj.onc.1210828;
RA   Enomoto A., Kido N., Ito M., Morita A., Matsumoto Y., Takamatsu N.,
RA   Hosoi Y., Miyagawa K.;
RT   "Negative regulation of MEKK1/2 signaling by serine-threonine kinase
RT   38 (STK38).";
RL   Oncogene 27:1930-1938(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-297; SER-300;
RP   SER-507 AND SER-1018, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275 AND SER-292, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-35; SER-275;
RP   THR-285; SER-292; SER-531; SER-923 AND SER-1018, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-92 AND SER-443.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [14]
RP   VARIANTS SRXY6 PRO-189; ARG-189; ILE-GLN-211 INS AND ARG-616, AND
RP   CHARACTERIZATION OF VARIANTS SRXY6 PRO-189 AND ARG-189.
RX   PubMed=21129722; DOI=10.1016/j.ajhg.2010.11.003;
RA   Pearlman A., Loke J., Le Caignec C., White S., Chin L., Friedman A.,
RA   Warr N., Willan J., Brauer D., Farmer C., Brooks E., Oddoux C.,
RA   Riley B., Shajahan S., Camerino G., Homfray T., Crosby A.H.,
RA   Couper J., David A., Greenfield A., Sinclair A., Ostrer H.;
RT   "Mutations in MAP3K1 cause 46,XY disorders of sex development and
RT   implicate a common signal transduction pathway in human testis
RT   determination.";
RL   Am. J. Hum. Genet. 87:898-904(2010).
CC   -!- FUNCTION: Component of a protein kinase signal transduction
CC       cascade. Activates the ERK and JNK kinase pathways by
CC       phosphorylation of MAP2K1 and MAP2K4. Activates CHUK and IKBKB,
CC       the central protein kinases of the NF-kappa-B pathway.
CC       {ECO:0000269|PubMed:9808624}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by autophosphorylation on Thr-1400
CC       and Thr-1412 following oligomerization.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates
CC       in multimolecular complexes through its N-terminus. Oligomerizes
CC       after binding MAP4K2 or TRAF2. Interacts with AXIN1. Interacts
CC       (via the kinase catalytic domain) with STK38.
CC       {ECO:0000269|PubMed:12223491, ECO:0000269|PubMed:15262978,
CC       ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:9808624}.
CC   -!- INTERACTION:
CC       P32121:ARRB2; NbExp=2; IntAct=EBI-49776, EBI-714559;
CC       P15056:BRAF; NbExp=2; IntAct=EBI-49776, EBI-365980;
CC       P61962:DCAF7; NbExp=7; IntAct=EBI-49776, EBI-359808;
CC       O75369:FLNB; NbExp=2; IntAct=EBI-49776, EBI-352089;
CC       P45985:MAP2K4; NbExp=3; IntAct=EBI-49776, EBI-447868;
CC       Q12851:MAP4K2; NbExp=2; IntAct=EBI-49776, EBI-49783;
CC       Q12933:TRAF2; NbExp=2; IntAct=EBI-49776, EBI-355744;
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- DISEASE: 46,XY sex reversal 6 (SRXY6) [MIM:613762]: A disorder of
CC       sex development. Affected individuals have a 46,XY karyotype but
CC       present as phenotypically normal females.
CC       {ECO:0000269|PubMed:21129722}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC008937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF042838; AAC97073.1; -; mRNA.
DR   EMBL; U29671; AAB05828.1; -; Genomic_DNA.
DR   CCDS; CCDS43318.1; -.
DR   PIR; G01887; G01887.
DR   RefSeq; NP_005912.1; NM_005921.1.
DR   UniGene; Hs.653654; -.
DR   ProteinModelPortal; Q13233; -.
DR   SMR; Q13233; -.
DR   BioGrid; 110378; 133.
DR   DIP; DIP-27520N; -.
DR   IntAct; Q13233; 39.
DR   MINT; MINT-143285; -.
DR   STRING; 9606.ENSP00000382423; -.
DR   BindingDB; Q13233; -.
DR   ChEMBL; CHEMBL3956; -.
DR   DrugBank; DB06061; AZD-8330.
DR   GuidetoPHARMACOLOGY; 2069; -.
DR   iPTMnet; Q13233; -.
DR   PhosphoSitePlus; Q13233; -.
DR   BioMuta; MAP3K1; -.
DR   DMDM; 218512139; -.
DR   SWISS-2DPAGE; Q13233; -.
DR   EPD; Q13233; -.
DR   MaxQB; Q13233; -.
DR   PaxDb; Q13233; -.
DR   PeptideAtlas; Q13233; -.
DR   PRIDE; Q13233; -.
DR   DNASU; 4214; -.
DR   Ensembl; ENST00000399503; ENSP00000382423; ENSG00000095015.
DR   GeneID; 4214; -.
DR   KEGG; hsa:4214; -.
DR   UCSC; uc003jqw.5; human.
DR   CTD; 4214; -.
DR   DisGeNET; 4214; -.
DR   GeneCards; MAP3K1; -.
DR   GeneReviews; MAP3K1; -.
DR   H-InvDB; HIX0024789; -.
DR   HGNC; HGNC:6848; MAP3K1.
DR   HPA; CAB004500; -.
DR   HPA; HPA046509; -.
DR   MalaCards; MAP3K1; -.
DR   MIM; 600982; gene.
DR   MIM; 613762; phenotype.
DR   neXtProt; NX_Q13233; -.
DR   OpenTargets; ENSG00000095015; -.
DR   Orphanet; 242; 46,XY complete gonadal dysgenesis.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   PharmGKB; PA30592; -.
DR   eggNOG; KOG4279; Eukaryota.
DR   eggNOG; ENOG410XQGS; LUCA.
DR   GeneTree; ENSGT00800000124036; -.
DR   HOGENOM; HOG000113437; -.
DR   HOVERGEN; HBG006302; -.
DR   InParanoid; Q13233; -.
DR   KO; K04416; -.
DR   OMA; STHFTRM; -.
DR   OrthoDB; EOG091G03WB; -.
DR   PhylomeDB; Q13233; -.
DR   TreeFam; TF105112; -.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; Q13233; -.
DR   SIGNOR; Q13233; -.
DR   GeneWiki; MAP3K1; -.
DR   GenomeRNAi; 4214; -.
DR   PRO; PR:Q13233; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000095015; -.
DR   CleanEx; HS_MAP3K1; -.
DR   Genevisible; Q13233; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IBA:GO_Central.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR007527; Znf_SWIM.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS50966; ZF_SWIM; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Complete proteome; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   1512       Mitogen-activated protein kinase kinase
FT                                kinase 1.
FT                                /FTId=PRO_0000086240.
FT   DOMAIN     1243   1508       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     338    366       SWIM-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00325}.
FT   ZN_FING     443    492       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   NP_BIND    1249   1257       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS      2      5       Poly-Ala.
FT   COMPBIAS     25     29       Poly-Gly.
FT   COMPBIAS     36     41       Poly-Ala.
FT   COMPBIAS    422    431       Poly-Ser.
FT   COMPBIAS    842    847       Poly-Ser.
FT   COMPBIAS    942    949       Poly-Thr.
FT   COMPBIAS   1182   1187       Poly-Glu.
FT   COMPBIAS   1216   1219       Poly-Ile.
FT   ACT_SITE   1369   1369       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING    1272   1272       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     137    137       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53349}.
FT   MOD_RES     154    154       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     275    275       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     285    285       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     292    292       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     300    300       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     507    507       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     531    531       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     923    923       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1018   1018       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1043   1043       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES    1400   1400       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1412   1412       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   VARIANT      92     92       S -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040680.
FT   VARIANT     189    189       L -> P (in SRXY6; increases
FT                                phosphorylation of the downstream target
FT                                MAPK3/MAPK1 compared to wild-type and
FT                                enhances binding of RHOA to the mutant
FT                                MAP3K1 complex; dbSNP:rs387906788).
FT                                {ECO:0000269|PubMed:21129722}.
FT                                /FTId=VAR_065504.
FT   VARIANT     189    189       L -> R (in SRXY6; increases
FT                                phosphorylation of the downstream targets
FT                                MAPK14 and MAPK3/MAPK1 compared to wild-
FT                                type and enhances binding of RHOA to the
FT                                mutant MAP3K1 complex;
FT                                dbSNP:rs387906788).
FT                                {ECO:0000269|PubMed:21129722}.
FT                                /FTId=VAR_065505.
FT   VARIANT     211    211       V -> VIQ (in SRXY6).
FT                                /FTId=VAR_065506.
FT   VARIANT     443    443       C -> S. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040681.
FT   VARIANT     616    616       G -> R (in SRXY6; dbSNP:rs143853590).
FT                                {ECO:0000269|PubMed:21129722}.
FT                                /FTId=VAR_065507.
FT   VARIANT     806    806       D -> N (in dbSNP:rs702689).
FT                                /FTId=VAR_051636.
FT   VARIANT     906    906       V -> I (in dbSNP:rs832582).
FT                                /FTId=VAR_051637.
FT   CONFLICT     20     20       T -> P (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT     37     37       P -> R (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    120    120       G -> R (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    351    351       R -> H (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    845    845       S -> SV (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    859    859       I -> Y (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    878    902       DGQQDSFLQASVPNNYLETTENSSP -> QRQQHNSFCRHL
FT                                FPTTIWKPQRTVPL (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT    933    933       S -> R (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT   1097   1097       C -> L (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT   1104   1107       AVIP -> CCYT (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
FT   CONFLICT   1200   1200       D -> V (in Ref. 2; AAC97073).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1512 AA;  164470 MW;  5CB78242295411D9 CRC64;
     MAAAAGNRAS SSGFPGARAT SPEAGGGGGA LKASSAPAAA AGLLREAGSG GRERADWRRR
     QLRKVRSVEL DQLPEQPLFL AASPPASSTS PSPEPADAAG SGTGFQPVAV PPPHGAASRG
     GAHLTESVAA PDSGASSPAA AEPGEKRAPA AEPSPAAAPA GREMENKETL KGLHKMDDRP
     EERMIREKLK ATCMPAWKHE WLERRNRRGP VVVKPIPVKG DGSEMNHLAA ESPGEVQASA
     ASPASKGRRS PSPGNSPSGR TVKSESPGVR RKRVSPVPFQ SGRITPPRRA PSPDGFSPYS
     PEETNRRVNK VMRARLYLLQ QIGPNSFLIG GDSPDNKYRV FIGPQNCSCA RGTFCIHLLF
     VMLRVFQLEP SDPMLWRKTL KNFEVESLFQ KYHSRRSSRI KAPSRNTIQK FVSRMSNSHT
     LSSSSTSTSS SENSIKDEEE QMCPICLLGM LDEESLTVCE DGCRNKLHHH CMSIWAEECR
     RNREPLICPL CRSKWRSHDF YSHELSSPVD SPSSLRAAQQ QTVQQQPLAG SRRNQESNFN
     LTHYGTQQIP PAYKDLAEPW IQVFGMELVG CLFSRNWNVR EMALRRLSHD VSGALLLANG
     ESTGNSGGSS GSSPSGGATS GSSQTSISGD VVEACCSVLS MVCADPVYKV YVAALKTLRA
     MLVYTPCHSL AERIKLQRLL QPVVDTILVK CADANSRTSQ LSISTLLELC KGQAGELAVG
     REILKAGSIG IGGVDYVLNC ILGNQTESNN WQELLGRLCL IDRLLLEFPA EFYPHIVSTD
     VSQAEPVEIR YKKLLSLLTF ALQSIDNSHS MVGKLSRRIY LSSARMVTTV PHVFSKLLEM
     LSVSSSTHFT RMRRRLMAIA DEVEIAEAIQ LGVEDTLDGQ QDSFLQASVP NNYLETTENS
     SPECTVHLEK TGKGLCATKL SASSEDISER LASISVGPSS STTTTTTTTE QPKPMVQTKG
     RPHSQCLNSS PLSHHSQLMF PALSTPSSST PSVPAGTATD VSKHRLQGFI PCRIPSASPQ
     TQRKFSLQFH RNCPENKDSD KLSPVFTQSR PLPSSNIHRP KPSRPTPGNT SKQGDPSKNS
     MTLDLNSSSK CDDSFGCSSN SSNAVIPSDE TVFTPVEEKC RLDVNTELNS SIEDLLEASM
     PSSDTTVTFK SEVAVLSPEK AENDDTYKDD VNHNQKCKEK MEAEEEEALA IAMAMSASQD
     ALPIVPQLQV ENGEDIIIIQ QDTPETLPGH TKAKQPYRED TEWLKGQQIG LGAFSSCYQA
     QDVGTGTLMA VKQVTYVRNT SSEQEEVVEA LREEIRMMSH LNHPNIIRML GATCEKSNYN
     LFIEWMAGGS VAHLLSKYGA FKESVVINYT EQLLRGLSYL HENQIIHRDV KGANLLIDST
     GQRLRIADFG AAARLASKGT GAGEFQGQLL GTIAFMAPEV LRGQQYGRSC DVWSVGCAII
     EMACAKPPWN AEKHSNHLAL IFKIASATTA PSIPSHLSPG LRDVALRCLE LQPQDRPPSR
     ELLKHPVFRT TW
//
